Alembic Pharmaceuticals Limited (APLLTD) — Announcement | 19 June 2026

StockFin.ai

Try Free

📢 Key Event
Alembic receives USFDA tentative approval for Binimetinib 45 mg tablets

💡 Investor Takeaway
Investors should note this approval could unlock future revenue from a high-value oncology indication.

Alembic Pharmaceuticals announced that its USFDA tentative approval for Binimetinib 45 mg tablets has been granted, marking the first Paragraph IV filing for this indication and positioning the company to potentially capture a $259 million market opportunity in melanoma and NSCLC treatments.

📄 View Original Announcement (PDF)

📊 Stock Analysis — APLLTD ✨ Ask AI About This

About Alembic Pharmaceuticals Limited (APLLTD)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹15,412.51 Cr P/E: 22.9 ROE: 11.8% ROCE: 11.2%

View full APLLTD stock details →

📡 Get AI alerts when APLLTD files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track APLLTD — Free

💡 Ask AI about this filing

"How does this affect APLLTD margins?" "Compare with last quarter results" "What should investors watch for?"

Ask AI Free →

📊 More APLLTD filings

See all APLLTD filings →

🔥 Also filed on 19 June 2026

SOMANYCERA Somany Ceramics Limited Corporate Action ESCORTS Escorts Kubota Limited Annual Report ORIENTTECH Orient Technologies Limited Announcement STLNETWORK STL Networks Limited Announcement ICIL Indo Count Industries Limited Announcement MODIS Modis Navnirman Limited Announcement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when APLLTD files new disclosures

Track APLLTD filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track APLLTD — Free

Free account · 2 AI queries/day